eprodisate

Eprodisate is a small molecule glycosaminoglycan mimetic developed to treat Amyloid A (AA) amyloidosis. It works by competitively binding to the glycosaminoglycan binding sites on serum amyloid A (SAA), thereby inhibiting the formation of glycosaminoglycan–amyloid fibril aggregates and preventing new amyloid deposits in organs such as the kidneys[1][2][6]. Eprodisate is structurally similar to heparan sulfate and disrupts interactions between amyloidogenic proteins and glycosaminoglycans, impeding polymerization of amyloid fibrils[5][6]. The drug was primarily developed for AA amyloidosis-related renal disease but has also been investigated for other indications. Eprodisate was originally developed by BELLUS Health (formerly Neurochem) and later acquired by GSK[4][7].

Brand names

KiactaFibrillex

Other names

eprodisate disodiumeprodisate sodium1,3-propanedisulfonic acidpropane-1,3-disulfonic acidpropane-1,3-disulphonate